BIODEGRADABLE INJECTABLE DELIVERY SYSTEM FOR NALTREXONE

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$49,900.00
Award Year:
1991
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
16813
Agency Tracking Number:
16813
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
1625 Sharp Point Dr, Box 20150, Fort Collins, CO, 80522
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Arthur Tipton
(303) 482-5868
Business Contact:
() -
Research Institution:
n/a
Abstract
NALTREXONE IS AN EFFECTIVE NARCOTIC ANTAGONIST. HOWEVER, ITS EFFECTIVENESS IS LIMITED BY THE NEED FOR HIGH PATIENT COMPLIANCE, AS ORAL DOSAGES MUST BE TAKEN AT LEAST THREE TIMES WEEKLY. BY USING A PROPRIETARY DELIVERY SYSTEM, IT ISEXPECTED THAT NALTREXONE CAN BE DELIVERED AT A CONTROLLED RATE FOR ONE MONTH. THE DELIVERY SYSTEM TO STUDIED IS BIODEGRADABLE AND BIOCOMPATIBLE, AND HAS BEEN SHOWN TO CAUSENO ADVERSE TISSUE REACTIONS IN ANIMAL TESTING. IT HAS BEEN STUDIED IN VITRO FOR THE CONTROLLED RELEASE OF SEVERAL DRUGS AND IS CURRENTLY BEING STUDIED IN HUMANS UNDER A PHASEII IND. MOST IMPORTANTLY, IT CAN BE INJECTED USING STANDARDSYRINGES AND NEEDLES. NALTREXONE WILL BE INCORPORATED INTO THIS DELIVERY SYSTEM. THE EFFECT OF SEVERAL VARIABLES INCLUDING DRUG FORM AND POLYMER COMPOSITION, MOLECULAR WEIGHT AND CONCENTRATION, WILL BE STUDIED IN ORDER TO OBTAIN THE DESIRED RELEASE PROFILE OF 5 MG/DAY. THE MOST PROMISING FORMULATION WILL BETESTED IN RABBITS FOR TISSUE COMPATIBILITY. NALTREXONE IS AN EFFECTIVE NARCOTIC ANTAGONIST. HOWEVER, ITS EFFECTIVENESS IS LIMITED BY THE NEED FOR HIGH PATIENT COMPLIANCE, AS ORAL DOSAGES MUST BE TAKEN AT LEAST THREE TIMES WEEKLY. BY USING A PROPRIETARY DELIVERY SYSTEM, IT ISEXPECTED THAT NALTREXONE CAN BE DELIVERED AT A CONTROLLED RATE FOR ONE MONTH. THE DELIVERY SYSTEM TO STUDIED IS BIODEGRADABLE AND BIOCOMPATIBLE, AND HAS BEEN SHOWN TO CAUSENO ADVERSE TISSUE REACTIONS IN ANIMAL TESTING. IT HAS BEEN STUDIED IN VITRO FOR THE CONTROLLED RELEASE OF SEVERAL DRUGS AND IS CURRENTLY BEING STUDIED IN HUMANS UNDER A PHASEII IND. MOST IMPORTANTLY, IT CAN BE INJECTED USING STANDARDSYRINGES AND NEEDLES. NALTREXONE WILL BE INCORPORATED INTO THIS DELIVERY SYSTEM. THE EFFECT OF SEVERAL VARIABLES INCLUDING DRUG FORM AND POLYMER COMPOSITION, MOLECULAR WEIGHT AND CONCENTRATION, WILL BE STUDIED IN ORDER TO OBTAIN THE DESIRED RELEASE PROFILE OF 5 MG/DAY. THE MOST PROMISING FORMULATION WILL BETESTED IN RABBITS FOR TISSUE COMPATIBILITY.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government